UNITY Biotechnology Inc
UBX0.200USD
0.000
Close 09/19, 16:00（ET）Quotes delayed by 15 min
3.44MMarket Cap
LossP/E TTM
More Details of UNITY Biotechnology Inc Company
Unity Biotechnology, Inc. is a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging. The Company is focused on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. It is targeting specific biological mechanisms implicated in diseases of aging. Its core therapeutic approach targets cellular senescence and is advancing senolytic programs primarily in ophthalmologic disorders. In addition, it has other programs based on other biologies of aging to include an agonistic antibody to the Tie2 receptor and a Tie2/VEGF bispecific to treat vascular eye disease. UBX1325 is its advanced lead drug candidate for age-related diseases of the eye, including diabetic macular edema. UBX1967 is its back-up compound to UBX1325. UBX2089, an α-Klotho hormone drug candidate, which is being researched for multiple neurology indications.
Company Info
Ticker SymbolUBX
Company nameUNITY Biotechnology Inc
IPO dateMay 03, 2018
CEO- -
Number of employees16
Security typeEquity Cash Option
Fiscal year-endMay 03
Address285 East Grand Avenue
CitySOUTH SAN FRANCISCO
Stock exchangeEurex
CountryUnited States of America
Postal code94080
Phone16504161192
Websitehttps://unitybiotechnology.com/
Ticker SymbolUBX
IPO dateMay 03, 2018
CEO- -
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Craig R. Jalbert
Mr. Craig R. Jalbert
President, Principal Executive Officer, Principal Financial Officer, Principal Accounting Officer, Corporate Secretary, Director
President, Principal Executive Officer, Principal Financial Officer, Principal Accounting Officer, Corporate Secretary, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Craig R. Jalbert
Mr. Craig R. Jalbert
President, Principal Executive Officer, Principal Financial Officer, Principal Accounting Officer, Corporate Secretary, Director
President, Principal Executive Officer, Principal Financial Officer, Principal Accounting Officer, Corporate Secretary, Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Aug 19
Updated: Tue, Aug 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
ARCH Venture Partners
5.84%
The Vanguard Group, Inc.
3.91%
Geode Capital Management, L.L.C.
0.98%
Ghosh (Anirvan)
0.80%
UBS Financial Services, Inc.
0.73%
Other
87.74%
Shareholders
Shareholders
Proportion
ARCH Venture Partners
5.84%
The Vanguard Group, Inc.
3.91%
Geode Capital Management, L.L.C.
0.98%
Ghosh (Anirvan)
0.80%
UBS Financial Services, Inc.
0.73%
Other
87.74%
Shareholder Types
Shareholders
Proportion
Investment Advisor
6.60%
Venture Capital
6.12%
Individual Investor
1.90%
Investment Advisor/Hedge Fund
1.41%
Endowment Fund
0.72%
Hedge Fund
0.59%
Bank and Trust
0.16%
Research Firm
0.14%
Other
82.37%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
89
3.22M
18.71%
-1.65M
2025Q1
97
3.46M
20.17%
-1.23M
2024Q4
105
3.52M
20.91%
-1.73M
2024Q3
123
3.68M
21.86%
-2.33M
2024Q2
132
4.12M
53.35%
-2.10M
2024Q1
133
4.24M
54.22%
-1.90M
2023Q4
140
4.96M
58.51%
+317.31K
2023Q3
176
3.32M
51.30%
-1.44M
2023Q2
196
3.34M
51.73%
-2.14M
2023Q1
225
3.87M
55.51%
-2.92M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
ARCH Venture Partners
1.00M
5.84%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
673.09K
3.91%
+82.32K
+13.93%
Mar 31, 2025
Geode Capital Management, L.L.C.
166.21K
0.97%
+6.81K
+4.27%
Mar 31, 2025
Ghosh (Anirvan)
138.45K
0.8%
-89.68K
-39.31%
Apr 10, 2025
Mayo Clinic
124.08K
0.72%
--
--
Sep 30, 2024
Renaissance Technologies LLC
94.21K
0.55%
+17.30K
+22.49%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
81.40K
0.47%
--
--
Mar 31, 2025
Sullivan (Lynne Marie)
72.30K
0.42%
-19.18K
-20.96%
Apr 10, 2025
David (Nathaniel E)
58.94K
0.34%
--
--
Apr 10, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Oct 19, 2022
Merger
10→1
Oct 19, 2022
Merger
10→1
Oct 19, 2022
Merger
10→1
Oct 19, 2022
Merger
10→1
Date
Type
Ratio
Oct 19, 2022
Merger
10→1
Oct 19, 2022
Merger
10→1
Oct 19, 2022
Merger
10→1
Oct 19, 2022
Merger
10→1
